Literature DB >> 17210122

Increased SOCS6 stability with PMA requires its N-terminal region and the Erk pathway via Pkcdelta activation.

Mi-Na Hwang1, Tae Hun Ha, Jongsun Park, Jaegal Shim, Ho Lee, Young-Nyun Kim, Eun Sook Lee, Sungpil Yoon.   

Abstract

We investigated stability of the ectopically expressed the SOCS6 protein in HEK293T cells with PMA, which activates protein kinase C (PKC). The treatment of PMA could largely increase SOCS6 stability in HEK293T cells. But, we did not observe increased protein levels of SOCS3 or Erk1 with PMA. This result suggests that the increased stability of SOCS6 with PMA did not generally occur in other proteins. The stability of SOCS6 depended on the N-terminal region containing an unidentified domain. We then studied the role of signal pathways in SOCS6 stability with PMA. We found that both Erk and Pkcdelta activation were required for the increased SOCS6 stability by PMA. The Erk activation by PMA appeared to be downstream from the Pkcdelta activation. The increased SOCS6 stability and Erk activation by PMA were both conserved in another cell line, MCF7. In addition, we demonstrated that PMA, insulin, and PDGF increased both the stability of endogenous-expressed SOCS6 and Erk activation in MDA-MB231 cells. These observations suggest that Erk activation may be correlated in the cells with high expression of SOCS6.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17210122     DOI: 10.1016/j.bbrc.2006.12.175

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  6 in total

1.  Salinomycin sensitizes cancer cells to the effects of doxorubicin and etoposide treatment by increasing DNA damage and reducing p21 protein.

Authors:  Ju-Hwa Kim; Minji Chae; Won Ki Kim; You-Jin Kim; Han Sung Kang; Hyung Sik Kim; Sungpil Yoon
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

Review 2.  SOCS6 is a selective suppressor of receptor tyrosine kinase signaling.

Authors:  Nuzhat N Kabir; Jianmin Sun; Lars Rönnstrand; Julhash U Kazi
Journal:  Tumour Biol       Date:  2014-08-30

3.  Expression of SOCSs in human prostate cancer and their association in prognosis.

Authors:  Jian-guo Zhu; Qi-shan Dai; Zhao-dong Han; Hui-chan He; Ru-jun Mo; Guo Chen; Yan-fei Chen; Yong-ding Wu; Sheng-bang Yang; Fu-neng Jiang; Wei-hong Chen; Zhao-lin Sun; Wei-de Zhong
Journal:  Mol Cell Biochem       Date:  2013-05-11       Impact factor: 3.396

Review 4.  SOCS proteins in regulation of receptor tyrosine kinase signaling.

Authors:  Julhash U Kazi; Nuzhat N Kabir; Amilcar Flores-Morales; Lars Rönnstrand
Journal:  Cell Mol Life Sci       Date:  2014-04-05       Impact factor: 9.261

5.  Suppressor of cytokine signalling-6 promotes neurite outgrowth via JAK2/STAT5-mediated signalling pathway, involving negative feedback inhibition.

Authors:  Sakshi Gupta; Kanchan Mishra; Avadhesha Surolia; Kakoli Banerjee
Journal:  PLoS One       Date:  2011-11-17       Impact factor: 3.240

6.  Novel Therapeutic Anti-ADAM17 Antibody A9(B8) Enhances EGFR-TKI-Mediated Anticancer Activity in NSCLC.

Authors:  Zheng Yang; Kin Iong Chan; Hang Fai Kwok; Kin Yip Tam
Journal:  Transl Oncol       Date:  2019-08-23       Impact factor: 4.243

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.